Neutralizing antibodies response to novel SARS-CoV-2 omicron sublineages in long-term care facility residents after the fourth dose of monovalent BNT162b2 COVID-19 vaccination

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiologic agent of the Coronavirus Disease 19 (COVID-19), has been progressively adapting to the human host since the beginning of the epidemic1. The Omicron variant, first identified in South Africa in November 2021, is the best adapted variant of concern (VOC), combining highly efficient binding to the ACE-2 cell receptor and immune escape. Since its emergence, Omicron has evolved into a plethora of descendant sublineages, including BA.1, BA.2, BA.3, BA.4, and BA.5.
Source: Journal of Infection - Category: Infectious Diseases Authors: Tags: Letter to the Editor Source Type: research